A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas

Lynn G Feun, David J. Stewart, Moshe Maor, Milam Leavens, Niramol Savaraj, M. Andrew Burgess, Wai Kwan A Yung, Robert S. Benjamin

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

A pilot study was performed combining cis-diamminedichloroplatinum (CDDP) and radiation therapy to treat patients with high-grade astrocytomas. CDDP at a dose of 40 mg/ m2/ week intravenously was given during the course of cranial irradiation. Following irradiation, CDDP was given every three weeks on a schedule of 35-40 mg/ m2/ day for three days until toxicity became unacceptable or until tumor progression occurred. Radiation therapy consisted of 6 000 rads over a seven week period or 5 000 rads followed by an additional 1500 rads to the tumor site. Patients were followed by computerized axial tomography (CT) scan and neurologic examination. Thirty patients were entered onto the study; 22 were considered evaluable. The median survival was 53 weeks and the median time to progression was 21 weeks. Toxicity was generally tolerable; however, ototoxicity may be enhanced by this treatment. CDDP combined with cranial irradiation is tolerable and feasible, although close follow-up is recommended in case CDDP has to be temporarily interrupted.

Original languageEnglish
Pages (from-to)109-113
Number of pages5
JournalJournal of Neuro-Oncology
Volume1
Issue number2
DOIs
StatePublished - Jun 1 1983
Externally publishedYes

Fingerprint

Astrocytoma
Cisplatin
Radiotherapy
Cranial Irradiation
Neurologic Examination
Neoplasms
Appointments and Schedules
Tomography
Survival

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas. / Feun, Lynn G; Stewart, David J.; Maor, Moshe; Leavens, Milam; Savaraj, Niramol; Burgess, M. Andrew; Yung, Wai Kwan A; Benjamin, Robert S.

In: Journal of Neuro-Oncology, Vol. 1, No. 2, 01.06.1983, p. 109-113.

Research output: Contribution to journalArticle

Feun, Lynn G ; Stewart, David J. ; Maor, Moshe ; Leavens, Milam ; Savaraj, Niramol ; Burgess, M. Andrew ; Yung, Wai Kwan A ; Benjamin, Robert S. / A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas. In: Journal of Neuro-Oncology. 1983 ; Vol. 1, No. 2. pp. 109-113.
@article{389e179a3ac24e58982110b31e26ac16,
title = "A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas",
abstract = "A pilot study was performed combining cis-diamminedichloroplatinum (CDDP) and radiation therapy to treat patients with high-grade astrocytomas. CDDP at a dose of 40 mg/ m2/ week intravenously was given during the course of cranial irradiation. Following irradiation, CDDP was given every three weeks on a schedule of 35-40 mg/ m2/ day for three days until toxicity became unacceptable or until tumor progression occurred. Radiation therapy consisted of 6 000 rads over a seven week period or 5 000 rads followed by an additional 1500 rads to the tumor site. Patients were followed by computerized axial tomography (CT) scan and neurologic examination. Thirty patients were entered onto the study; 22 were considered evaluable. The median survival was 53 weeks and the median time to progression was 21 weeks. Toxicity was generally tolerable; however, ototoxicity may be enhanced by this treatment. CDDP combined with cranial irradiation is tolerable and feasible, although close follow-up is recommended in case CDDP has to be temporarily interrupted.",
author = "Feun, {Lynn G} and Stewart, {David J.} and Moshe Maor and Milam Leavens and Niramol Savaraj and Burgess, {M. Andrew} and Yung, {Wai Kwan A} and Benjamin, {Robert S.}",
year = "1983",
month = "6",
day = "1",
doi = "10.1007/BF00182955",
language = "English",
volume = "1",
pages = "109--113",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas

AU - Feun, Lynn G

AU - Stewart, David J.

AU - Maor, Moshe

AU - Leavens, Milam

AU - Savaraj, Niramol

AU - Burgess, M. Andrew

AU - Yung, Wai Kwan A

AU - Benjamin, Robert S.

PY - 1983/6/1

Y1 - 1983/6/1

N2 - A pilot study was performed combining cis-diamminedichloroplatinum (CDDP) and radiation therapy to treat patients with high-grade astrocytomas. CDDP at a dose of 40 mg/ m2/ week intravenously was given during the course of cranial irradiation. Following irradiation, CDDP was given every three weeks on a schedule of 35-40 mg/ m2/ day for three days until toxicity became unacceptable or until tumor progression occurred. Radiation therapy consisted of 6 000 rads over a seven week period or 5 000 rads followed by an additional 1500 rads to the tumor site. Patients were followed by computerized axial tomography (CT) scan and neurologic examination. Thirty patients were entered onto the study; 22 were considered evaluable. The median survival was 53 weeks and the median time to progression was 21 weeks. Toxicity was generally tolerable; however, ototoxicity may be enhanced by this treatment. CDDP combined with cranial irradiation is tolerable and feasible, although close follow-up is recommended in case CDDP has to be temporarily interrupted.

AB - A pilot study was performed combining cis-diamminedichloroplatinum (CDDP) and radiation therapy to treat patients with high-grade astrocytomas. CDDP at a dose of 40 mg/ m2/ week intravenously was given during the course of cranial irradiation. Following irradiation, CDDP was given every three weeks on a schedule of 35-40 mg/ m2/ day for three days until toxicity became unacceptable or until tumor progression occurred. Radiation therapy consisted of 6 000 rads over a seven week period or 5 000 rads followed by an additional 1500 rads to the tumor site. Patients were followed by computerized axial tomography (CT) scan and neurologic examination. Thirty patients were entered onto the study; 22 were considered evaluable. The median survival was 53 weeks and the median time to progression was 21 weeks. Toxicity was generally tolerable; however, ototoxicity may be enhanced by this treatment. CDDP combined with cranial irradiation is tolerable and feasible, although close follow-up is recommended in case CDDP has to be temporarily interrupted.

UR - http://www.scopus.com/inward/record.url?scp=0020555713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020555713&partnerID=8YFLogxK

U2 - 10.1007/BF00182955

DO - 10.1007/BF00182955

M3 - Article

C2 - 6088710

AN - SCOPUS:0020555713

VL - 1

SP - 109

EP - 113

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -